Clinical trial RESGEX
Randomized, controlled, open-label, multicenter, phase II study to evaluate the efficacy and safety of CetuGEXTM plus chemotherapy in comparison to cetuximab plus chemotherapy for the treatment of patients with stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neck
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | Glycotope |
EudraCT Identifier | 2013-003695-13 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02052960 |
Inclusion criteria | EGFR+ |
Last update |